United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) antigen (formaldehyde inactivated) (unii: xw4jb03ti5) (influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:92xe6ghc89), influenza a virus a/kansas/14/2017 x-327 (h3n2) antigen (formaldehyde inactivated) (unii: 3nzw5nd3d6) (influenza a virus a/kansas/14/2017 x-327 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:k329ycd1n9), influenza b virus b/maryland/15/2016 bx-69a antigen (formaldeh - influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 60 ug in 0.5 ml - fluzone® high-dose is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b virus contained in the vaccine. fluzone high-dose is approved for use in persons 65 years of age and older. a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11) ], including egg protein, or to a previous dose of any influenza vaccine is a contraindication to administration of fluzone high-dose. fluzone high-dose is not approved for use in persons <65 years of age. there are limited human data and no animal data available to establish whether there is a vaccine-associated risk with use of fluzone high-dose in pregnancy. fluzone high-dose is not approved for use in persons <65 years of age. no human or animal data are available to assess the effects of fluzone high-dose on the breastfed infant or on milk production/excretion. safety and effectiveness of fluzone high-dose in persons <65 years of age have not bee

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

abbott biologicals b.v. veerweg 12 - influenza vaccine inactivated (surface antigen)-a/brisbane/02/2018 (h1n1) pdm-like strain (a/brisbane/02/2018, ivr-190), a/kansas/14/2017 (h3n2)-like strain (a/ a/kansas/14/2017, nymc x-327), b/colorado/06/2017-like strain (b/ victoria/2/87/ lineage) (b/maryland/15/2016, nymc bx-69 a) - suspension for injection - 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a/brisbane/02/2018 (h1n1) pdm09-like strain 15ug (a/brisbane/02/2018, ivr-190); influenza virus a/kansas/14/2017 (h3n2) like strain 15ug (a/kansas/14/2017, nymc x-327); influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a); influenza virus b/phuket/3073/2013 - like strain 15ug (b/ phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/brisbane/02/2018 (h1n1) pdm09-like strain 15ug (a/brisbane/02/2018, ivr-190) influenza virus a/kansas/14/2017 (h3n2) like strain 15ug (a/kansas/14/2017, nymc x-327) influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a) influenza virus b/phuket/3073/2013 - like strain 15ug (b/ phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate as dihydrate 0.67 mg magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines. influvac tetra (saison 2019/2020) is indicated in adults and children 3 years of age and older at low risk of complications from influenza.

Israel - English - Ministry of Health

neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أبوشيخة - abu sheikha drug store - b/brisbane/60/2008 15 mcg/1 amp, a/brisbane/02/2018 (h1n1)pdm09-like strain 15 mcg/1 amp, a/kansas/14/2017 (h3n2)-like strain 15 mcg/1 amp - 15 mcg/1 amp, 15 mcg/1 amp, 15 mcg/1 amp

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin -

Israel - English - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:- active immunisation of adults, including pregnant women, and children from 6 months of age and older- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women.the use of vaxigrip tetra should be based on official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - suspension - excipient ingredients: magnesium chloride hexahydrate; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; water for injections; potassium chloride; calcium chloride dihydrate; sodium chloride - for the prevention of influenza caused by influenza virus, types a and b.,for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.,influvac tetra is indicated in adults and children from 6 months of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - suspension - excipient ingredients: magnesium chloride hexahydrate; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; water for injections; potassium chloride; calcium chloride dihydrate; sodium chloride - for the prevention of influenza caused by influenza virus, types a and b.,for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.,influvac tetra is indicated in adults and children from 6 months of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - suspension - excipient ingredients: magnesium chloride hexahydrate; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; water for injections; potassium chloride; calcium chloride dihydrate; sodium chloride - for the prevention of influenza caused by influenza virus, types a and b.,for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.,influvac tetra is indicated in adults and children from 6 months of age and older.